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Abstract: The quantification of enzyme activity in the patient treated with enzyme replacement 
therapy (ERT) has been suggested as a tool for dosage individualisation, so we conducted a study to 
evaluate the relationship between glucocerebrosidase activity and clinical response in patients with 
Gaucher disease type I (GD1) to ERT. The study included patients diagnosed with GD1, who were 
being treated with ERT, and healthy individuals. Markers based on glucocerebrosidase activity 
measurement in patients’ leukocytes were studied: enzyme activity at 15 min. post-infusion (Act75) 
reflects the amount of enzyme that is distributed in the body post ERT infusion, and accumulated 
glucocerebrosidase activity during ERT infusion (Act75-0) indicates the total drug exposure during 
infusion. The clinical response was evaluated based on criteria established by Pastores et al. and 
Gaucher Severity Score Index. Statistical analysis included ROC analysis and area-under-curve test. 
Act75 and Act75-0 were found to be moderate predictive markers of an optimal clinical response (area 
under the ROC of Act75 was 0.733 and Act75-0 was 0.817). Act75-0 showed statistical significance in its 
discriminative capacity (p<0.05) for obtaining an optimal response to ERT. The cut-off point was 58% 
(RR=1.800;CI95% 1.003 to 3.229;p<0.05). Moreover, Act75 showed a significant and inverse 
correlation with the Gaucher Severity Score Index, and Act75 and Act75-0 presented a significant 
correlation with residual enzyme activity at diagnosis. Markers based on glucocerebrosidase activity 
have a good correlation with clinical response to ERT. Therefore, it could provide supporting clinical 
data for dose management in GD1 patients. 
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Gaucher disease (GD) is a rare, inherited metabolic disorder caused by a partial or total deficiency of 
lysosomal beta-glucocerebrosidase (GCase), which leads to a decrease in hydrolysis of 
glucocerebroside and its subsequent storage in cell lysosomes in the monocyte/macrophage system. 
Clinical symptomatology of the disease derives from accumulation of glucocerebroside in the 
lysosomes of these cells (named Gaucher cells) and later on in different tissues, producing a multi-
systemic disorder[1]. The most common variant is the non-neuropathic form, Gaucher disease type I 
(GD1), whose diagnosis is currently based on the presence of clinical signs and symptoms, although 
the “gold standard” is detection of low GCase activity intra-leukocyte [2-5]. 
Treatment for GD1 is based on the administration of enzyme replacement therapy (ERT), which 
improves haematological parameters and leads to a stabilisation or reduction of bone and visceral 
lesions[6]. The therapeutic enzyme is designed to be internalized by monocyte/macrophage through 
receptor-mediated endocytosis via mannosa receptors. This receptor is a member of the family type 
lectin receptor expressed in macrophages/monocytes, dendritic cells and hepatic cells and lymphatic 
endothelium[7].  
There are currently three drugs marketed for ERT: imiglucerase (IMG;Cerezyme® Genzyme, Sanofi 
Company), velaglucerase (VELA;Vprip® Shire Pharmaceuticals SL) and taliglucerase (TAL; Elelyso®, 
Pfizer SLU)[8-11]. Nowadays, the selection of the appropriate dose to be used in ERT and other 
clinical decisions are based on recommendations published by Pastores et al., that define an optimal 
response (OR) if at least five of six therapeutic goals described in the six domains of GD1 
(haemoglobin, platelets, splenic and hepatic volume, chitotriosidase and bone pain) are met and a 
non-optimal response (NOR) when they are not met[12]. Other important score that reflects 
variations in disease severity induced by treatment is the Gaucher Severity Score Index-type I 
(GauSSI-I). This score has a maximum of 42 points, distributed over six different domains (skeletal, 
hematologic, chitotriosidase, visceral, lung and neurological)[13]. Currently, dosage individualisation 
consists of selecting a maintenance dose at levels ranging between the initial recommended dose 
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(60 U/kg/14days) and the minimum established effective dose, which is 15 U/kg/14days. Despite an 
increase in the acceptance of this tendency, the most convenient dosage regimen design for ERT in 
patients with GD1 remains controversial in several aspects, such as the differential effect of enzymes 
in patients, the efficacy of a high-dose or a low-dose treatment schedule, the so-called poor 
responder patients in which increasing doses do not increase the rate of response, or administration 
of the ERT infusion once every 4 weeks in stable patients [6, 14-17]. 
Published studies on the pharmacokinetics of ERT[9, 10, 18, 19] have suggested that, after 
intravenous administration, the activity of circulating enzyme decreases rapidly in plasma because of 
the principal distribution model of the ERT is through uptake by mannose-6-phosphate (M6P) into 
peripheral monocytes and their distribution in tissues as macrophages. A direct extravasation to 
tissues through the vascular endothelium with subsequent uptake by macrophages is theoretically 
less important or null due to its high molecular weight (70KDa), which causes the tissue distribution 
of most proteins to be limited to the vascular or interstitial spaces[20].   
Consequently, as monocyte/macrophage system, a type of polymorphonuclear leukocyte 
(monocytes in circulation and macrophages in tissues), are the target cells in GD1, hence the 
quantification of intra-leukocyte enzyme activity in patients treated with ERT could be used as a tool 
to monitor ERT. Moreover, intra-leukocyte enzymatic activity seems to show a linear correlation 
with the low or intermediate doses studied [21-23]. However, studies of high doses have suggested a 
non-linear pharmacokinetic[9, 10].  
Thus, due to the variability in dose and frequency of ERT, the variability of response to ERT and the 
high cost of these therapies[24], this study was carried out in order to accurately assess the relative 
efficacy of treatment and to identify tools for ERT individualisation. For this purpose, the relationship 
between GCase intra-leukocyte activity and clinical response in patients with GD1 treated with ERT 
was evaluated. 
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
 
MATERIAL AND METHODS 
A prospective follow-up, experimental multicentre study was conducted in four public hospitals from 
June 2014 to May 2015. The study was carried out with the approval of the Clinical Research Ethics 
Committee and after obtaining the informed consent of the patients. 
Healthy individuals were included as controls to establish the normal cut-off points of GCase activity 
in peripheral blood leukocytes. Adult patients (>18 years) with GD1 confirmed by enzyme diagnosis 
who had been receiving stable doses (without changes of doses or frequencies) of ERT treatment for 
at least 12 months prior to inclusion in the study were included.  
The ERT drugs (IMG, VELA and TALI) used in the study were prepared in 0.9% saline solution. 
Administration was carried out by nursing staff at each health centre for a period of 60 min. 
according to the specifications of the Product Characteristics Summary[8-10]. 
Analytical assays 
Two blood samples were taken from each patient in a tube with EDTA on two occasions: prior to the 
start of the infusion with the exogenous enzyme, this was done in order to calculate enzyme activity 
at time zero (Act0); and 15-min. post-infusion, to calculate enzyme activity at time 75 min. (Act75). An 
aliquot of leukocytes was extracted from each blood sample and analytical assay by high 
performance liquid chromatography (HPLC) with fluorometric detection were conducted: enzymatic 
reaction between GCase and the substrate 4-methylumbellferyl-β-D-glucoside and sodium 
taurocholate as detergent with the product formed being 4-methylumbelliferone that is determined 
by HPLC with fluorimetric detection [25]. This analysis has an incubation time of 60 min. The 
enzymatic activity was expressed as the number of enzyme units per litre of solution (U/L). 
Enzyme activity was measured in leukocytes (instead of monocytes) because activity of Gcase in 
monocyte represents 96% of total leukocyte approximately [26]. Analysing GCase in total leukocytes 
simplifies the analytical method for use in routine clinical practice, allows comparing with the 
activity measure at diagnosis, which carries out in leukocytes [27]. 
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Variables and GCase-based markers  
The variables studied were: monthly doses (U/kg/4w); ferritin (ng/mL); chitotriosidase (CT) 
(nmol/mL.h) or PARC/CCL18 (ng/mL) which are biomarkers secreted by the Gaucher cells and reflect 
the total body burden of storage cells in patients with GD1. GCase-based markers were: ActD  
endogenous enzyme activity measured at diagnosis and expressed as percentage with respect to the 
healthy individual activity  was quantified in a reference centre at the time of diagnosis, using 
Raghavan’s[28] and Chamoles’ [29] analytical methods for peripheral blood leukocytes and dried 
blood spot samples, respectively. These values were collected from medical history; Act0  enzyme 
activity from the residual exogenous enzyme in peripheral leukocytes after previous infusions plus 
each patient’s own residual endogenous enzyme , measured prior to ERT and analysed locally at 
our centre; Act75  enzyme activity measured as the maximum concentration reached in leukocytes 
after ERT, measured 15 min. after infusion and analysed locally at our centre; Act75-0  enzyme 
activity accumulated during the ERT, calculated as the difference between Act75 and Act0. All the 
GCase-based markers were expressed in raw value and in percentage with respect to the healthy 
individual activity. 
Data on clinical variables that support patient follow-up were collected when patients entered the 
study using the following tools: 
The clinical response to ERT was calculated based on criteria established by Pastores et al. [12] that 
define an Optimal Response (OR) if 5/6 clinical criteria are met and a non-optimal response (NOR) 
when ≤4/6 criteria are met. The 6 parameters considered to evaluate OR/NOR are: Haemoglobin ≥ 
11.0g/dL in women and ≥12.0g/dL in men; Platelets ≥120·109/L; Splenic volume <5 times normal 
value; Hepatic volume <1.25 times normal value; CT <600 nmol/mL·h; bone involvement, valued as 
bone pain ≤2 on the EVA scale and without the appearance of bone crises in 6 months.  
GauSSI-I is a reliable method for staging the severity of adult GD1, and sensitive method for 
measuring changes in disease severity caused by therapy. It has a maximum of 42 points, distributed 
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over six different domains with unequally weighted parameters, skeletal (bone marrow infiltration 
and bone mineral component subdomains), hematologic and visceral domain represented 76% of 
points[13]. In this study, we used several tools to measure clinical response, due to the different 
weight of each of the clinical domains in each one and because they are the most widely used scales 
in clinical practice for monitoring patients with GD. 
Other clinical data collected were: physical and mental quality of life assessment using SF36 [30], the 
S-MRI scale for infiltration in the bone marrow [31] and the Zimran severity scale (SSI) [32] measured 
on diagnosis. 
 
Statistical analysis 
The statistical analysis was conducted using the SPSS v19 statistical software (IBM SPSS Inc., Chicago, 
USA). The receiver operating characteristic (ROC) curve was applied and the area under the curve 
(AUC) was studied according to the OR with the objective of detecting markers related to enzyme 
activity with the greatest discriminative capacity for obtaining the OR to the ERT. The AUC was used 
to distinguish whether a marker was non-predictive (AUC≤0.5), less predictive (0.5<AUC<0.7), 
moderately predictive (0.7<AUC<0.9), highly predictive (0.9<AUC<1)[33]. Sensitivity (Se), specificity 
(Sp) and cut-off points for the markers studied were analysed. The Chi-square (χ2) test and relative 
risk of the cut-off point of markers was applied.  
The mean difference in parameters studied according to the clinical response reached was analysed 
using non-parametric tests: the Mann-Whitney U-test. 
The correlation studies for activity markers with GauSSI-I and other quantitative clinical variables 
and its cut-off point were conducted using the Spearman Rho correlation coefficient with bilateral 
signification.  
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RESULTS 
Population and normal values 
A total of 19 patients diagnosed with GD1 and 10 healthy individuals were included in the study. 
Mean total GCase intra-leukocyte activity in healthy patients measured by fluorometric detection 
was 121.84 U/L (CI95% 101.99 to 141.69; CV 8.2%). Table 1 shows the clinical, biometric and dosage 
characteristics of the 19 GD1 patients included in the study. Of the 19 GD1 patients, 4 of them had 
non-optimal response to ERT.  
Relationship of GCase-based markers and variables with clinical response 
The mean values of the GCase-based markers in percentage with respect to the healthy individual 
activity and variables studied, and the results of the ROC curve of the patients included in the study 
are shown in Table 2.  
Similar results were observed in analysis with raw values and in analysis with percentage values; AUC 
were: Act0 = 0.505(CI95%: 0.254 a 0.757); Act75 = 0.763 (CI95%:0.625 a 0.902); Act75-0 =0.837 (CI95%: 
0.635 a 0.938). The mean values according to optimal response were similar, too: Act0 was 69.59 (SD 
67.07) and 38.18 (SD 50.92) for OR and NOR; Act75 was 189.35 (SD 140.21) and 71.47 (SD 75.89) for 
OR and NOR; Act75-0 was 119.76 (SD 103.98) and 33.28 (SD 28.56) for OR and NOR. As analysis with 
percentage values (table 2), the only marker with statistical significance was Act75-0. 
Moderately predictive markers for optimal response (OR) were Act75 and Act75-0 but statistically 
significant differences on the AUC ROC curve were only detected for Act75-0. Fig. 1 represents ROC 
curve for Act75-0.  
The association between the cut-off point of 58% of the Act75-0 and OR to the treatment presented a 
Chi-square of 5.630 with statistical significance (p=0.018) and a relative risk of 1.800 (IC95% 1.003 to 
3.229) representing a probability of 64% of obtaining an OR to ERT.  
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Table 2 also presents the average values and the dispersion (SD) of the variables and markers 
studied according to the OR/NOR of the patients and their statistical significance. Also, the marker 
Act75-0 presented significant differences (p<0.05) between the mean values of patients with OR and 
NOR. 
 
Relationship of GCase-based markers with clinical variables 
The correlation between the clinical variables and Act75 and Act75-0 (Table 3) was studied. Act75 and 
Act75-0 presented significant and positive correlation with ActD. GauSSI-I showed negative and 
significant correlation with Act75. The rest of the clinical variables presented non-significant negative 
linear correlation with Act75 and Act75-0. Table 3 also shows the mean values of the individual clinical 
variables according to the cut-off point of 58% Act75-0. ActD showed significant differences. 
 
DISCUSSION 
This is the first study to evaluate the relationship between intra-leukocyte enzymatic activity and 
clinical response in patients with GD1. It shows that GCase intra-leukocyte activity has correlation 
with clinical response: on the one hand, Act75, the amount of enzyme inside the leukocyte 15-min. 
post ERT infusion, has an inverse and significant relationship with GauSS-I; thus, patients with low 
enzyme concentrations inside leukocyte post ERT infusion, have more severe Gaucher disease. 
Moreover, Act75 is a moderately predictive marker for optimal response based on criteria by 
Pastores et al. On the other hand, Act75-0, representing the total drug exposure during infusion, is 
also a moderately predictive marker for optimal response showing statistically significant difference.  
ERT for GD1 aims to replace deficient endogenous enzyme activity in patients. Therefore, it should 
be expected that ERT would achieve the resolution of clinical symptoms of the disease in all patients. 
However, there is evidence of high inter-individual variability in clinical response and patient 
evolution. It has been postulated that this is due to residual Gaucher cells that remain in the body 
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and are associated with a highest risk of long-term complications[34, 35]. Results reported in this 
study could contribute to explain, at least in part, the non-optimal response to ERT observed in some 
patients, since due to the exogenous enzyme does not enter into the monocyte-macrophage system 
in sufficient concentrations and therefore does not reach the target organs and does not reverse the 
symptoms. A number of causes have been postulated for this low penetration of the exogenous 
enzyme into monocyte-macrophage of GD1 patients. These include different macrophage 
immunophenotypes[10], the high variability of the M6P receptor[36], the saturation of the mannose 
receptor at high doses[9] or that the enzyme is eliminated by peptidases or outside of the vascular 
endothelium at a faster rate than the rate of uptake by the monocyte[18, 37]. 
GCase activity measurement could give an answer to these questions because if the amount of 
enzyme inside the leukocyte post ERT infusion (endogenous plus exogenous enzyme) is known and 
that is distributed throughout the body by monocyte-macrophages system, it could predict the 
patient’s clinical response. Results reported in this study suggest that Act75 could act as this marker. 
Moreover, Act75-0 calculated as the difference in GCase activity measured prior to ERT and 15 min. 
post-infusion, reflects the amount of exogenous enzyme uptake by the leukocyte could be a tool to 
detect non-responder patients to ERT, because exogenous enzymes do not penetrate in leukocytes.  
The mean values of Act75-0 and Act75 in patients who have OR to ERT have 98% (SD 85%) and 154% 
(SD 115%) of the enzyme activity of healthy individuals, while non-responding patients have much 
lower values as 27% (SD 23%) and 58% (SD 62%), respectively.  
High between subjects variability in the maximum activity achieved after the infusion into the 
leukocytes, which is later distributed throughout the organism (Act75) could be due to the patients 
have different values of endogenous enzyme and because the variability in the degree of exogenous 
enzyme uptake [18]. Therefore, the amount of enzyme that comes from the ERT (Act75-0) in patients 
with OR is virtually the same amount as healthy individuals have of endogenous enzyme. These data 
back the postulated hypothesis that is based on a low response rate can be explained because 
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patients’ leukocytes take up less exogenous enzyme; thus, this marker could detect and clarify non-
responding patients. 
The rising ROC curve reflects the trade-off existing between sensitivity and specificity and statistical 
significance was only observed with the marker Act75-0 (fig. 1) with a cut-off point of 58%. This result 
indicates that this marker is useful to detect patients who are poor responders although with a 
relatively low sensitivity. Thus, 44% of the patients who have been defined as non-responders 
(<58%) will have OR and will, therefore, be false negatives. However, the relative risk of this marker 
with the OR is 1.8; thus, patients with Act75-0 over 58% have an increased probability of 64% of 
obtaining an OR to ERT.  
Furthermore, we analysed raw values and in percentage relative to the normal one in order to check 
the accuracy of data. Results are similar because the variability of enzyme in healthy individuals was 
very small in our study (CV 8%) and when compared with other methods [(Raghavan CV=12,0%[28]; 
Peters CV=18,8%[25]; Beutler CV=21,4%[4]; Chamoles median 3.54U (min. 2.16 and max. 5.29) [29]]. 
The current gold standard marker for diagnosis of GD1 is an ActD enzyme activity value in leukocytes 
under 30% of the mean value in leukocytes obtained from healthy individuals. This study shows that 
patients with accumulated activities in leukocytes that are greater than 58% have a higher 
probability of an optimal response to ERT. These results match, because GCase deficiency under 30% 
and an exogenous enzyme replacement of 58% give values close to those of a healthy individual. 
In regard to the relationship between activity markers and the clinical variables, Act75 showed a 
significant and negative correlation with GauSS-I, that is, low Act75 values are correlated with 
greatest Gaucher Severity Score Index. However, patients included in this study have no severe GD 
with mean GauSS-I of 4.6 of 42 points in the score (table 3). 
Furthermore, Act75 and Act75-0 showed a significant and positive correlation with ActD. Similarly, 
Torralba et al. [38] recently defined a new criterion for the prognosis of the disease in addition to 
the diagnosis based on ActD: low ActD values are correlated with the greatest severity of GD1. 
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Results reported in this study indicate that ActD also shows correlation with the OR, although no 
statistical significance was obtained (Table 2), and there is a positive and linear correlation with 
Act75-0 and Act75 (Table 3), so that patients with low ActD also have low Act75-0 and Act75. In this 
sense, patients with an OR and NOR in our study have mean values of ActD of 12% and 4%, 
respectively. While these values do not reach statistical differentiation, probably due to the 
variability of the data and small population, it could be attributed that the patients with non-optimal 
response have much lower residual enzyme activities and a lower response to the ERT. Based on the 
results of this study, if patients have low ActD even though high doses of ERT have been 
administered, Act75-0 and Act75 values will not increase sufficiently in patients, and therefore, they 
will not achieve an OR to ERT. 
Nevertheless, in this study, there are three limitations, which must be taken into account; firstly, a 
small population, as is typical in rare diseases was included in the study, and all of them with a low 
to moderate severity of the disease, showing low score in GauSS-I. Secondly, the small number of 
NOR patients because the patients studied are being treated for a long time (mean 16 years) with 
ERT dose adjustments based on clinical guidelines. However, and despite of these limitations, 
reported results are the first and novel approach in this field and may have important clinical 
implications in ERT individualization in GD patients; nowadays, time to optimal response could be 
delayed until 2 years with the economic cost that the treatment involves. These markers can lead to 
anticipate these decisions. Finally, a pharmacokinetic and pharmacodynamic modelling approach 
would allow a better understanding of the distribution of ERT in patients and confirm GCase 
enzymatic activity as a marker for therapeutic individualization.  
In conclusion, the results of this study demonstrate that GCase-based activity markers (Act75-0 and 
Act75) have a good correlation with clinical response to ERT, and therefore it is possible to 
hypothesize that it could provide supporting clinical data for dose management in GD1 patients. 
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TABLE1. Baseline characteristics of patients receiving treatment with enzyme replacement therapy 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ERT: Enzyme replacement therapy; W:women; M: men; IMG: Imiglucerase; VELA: Velaglucerase; CT: chitotriosidase; GauSSI-I: the Gaucher Severity Score 
Index-type I; OR: optimal response; NOR: non-optimal response 
 
 
 
Patient 
nº 
Sex Genotype 
Weigh
t (kg) 
Age at 
diagnosis 
(years) 
Current 
age 
(years) 
ActD 
(%) 
Dose/kg 
(U/kg) 
Dosing 
interval 
(days) 
Time 
(years) 
in ERT 
CT 
(nmol/ml.h
) 
ERT 
GauSSI-I 
(0-44) 
Response  
(items 
reached of 6) 
1 M N370S/G195W 55 6 26 2.94 17.00 28 20 1003 IMG 5 NOR (4/6) 
2 W N370S/L444P 67 15 33 0.14 23.88 14 19 641 IMG 6 OR (5/6) 
3 W N370S/L444P 75 21 52 2.00 32.00 14 16 380 IMG 7 NOR (4/6) 
4 W N370S/L444P 49 27 33 3.00 24.49 14 5 363 IMG 3 OR (6/6) 
5 W N370S/N370S 51 28 49 18.75 15.69 14 22 614 IMG 2 OR (5/6) 
6 M N370S/N370S 80 28 52 15.63 30.00 14 19 323 IMG 0 OR (6/6) 
7 W N370S/N370S 51 28 49 18.75 15.69 14 22 359 IMG 2 OR (6/6) 
8 M N370S/DELTA 55 90 8 20 15.00 26.67 14 13 321 IMG 2 OR (6/6) 
9 W N370S/L444P 63 20 49 6.25 31.75 14 14 29 VELA 4 OR (6/6) 
10 W N370S/unknown 53 21 64 27.00 67.92 14 12 1005 VELA 4 OR (5/6) 
11 M N370S/L444P 107 25 54 33.00 29.91 14 17 47 VELA 7 OR (5/6) 
12 M N370S/N370S 84 27 52 16.00 33.33 14 8 431 IMG 8 OR (5/6) 
13 W N370S/N188S 38 39 56 6.88 11.00 28 19 157 IMG 4 OR (5/6) 
14 M N370S/N188S 104 15 53 6.88 35.29 14 19 771 IMG 6 OR (5/6) 
15 M LEU375Arg/N370S 75 49 57 10.00 42.67 14 10 274 IMG 8 NOR (4/6) 
16 W L444P/Gly416Ser 77 27 71 2.50 20.78 14 18 40 IMG 9 NOR (4/6) 
17 M N370S/p.Arg159Trp 80 10 43 5.00 15.00 28 14 135 IMG 2 OR (5/6) 
18 W N370S/p.Arg159Trp 46 13 38 3.75 34.78 14 21 72 IMG 3 OR (6/6) 
19 M N370S/L444P 75 29 36 6.88 60.00 14 7 265 VELA 6 OR (6/6) 
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TABLE 2.  Results of biomarkers studied according to the optimal response. Mean values and the dispersion of the variables and markers studied by 
fluorimetric detection according to the optimal or non-optimal response of the patients and its statistical significance  
 Parameter Mean (SD) 
Mean values according to Optimal Response ROC CURVE 
ERT Response Mean (SD) p-value AUC (IC95%) Cut off Se (%) Spe (%) 
Clinical parameters 
Ferritin (ng/ml) 395.22 (410.37) 
Optimal 405.79 (408.45) 
0.845 0.536 (0.290-0.769) 270.00 57 75 
Non-optimal 358.25 (478.52) 
ActD (%) 10.54 (9.07) 
Optimal 12.19 (9.43) 
0.057 0.807 (0.575-0.954) 2.97 93 75 
Non-optimal 4.36 (3.78) 
CT (nmol/ml.h) 380.56 (310.91) 
Optimal 368.87 (283.67) 
0.733 0.483 (0.252- 0.719) 522.00 27 75 
Non-optimal 424.00 (502.26) 
Therapy parameters 
Monthly doses 
(U/kg/4w) 
57.51 (32.25) 
Optimal 58.99 (33.78) 
0.920 0.518 (0.190 -0.846) 45.00 73 50 
Non-optimal 51.97 (29.38) 
Act0 (%)
†
 51.69 (52.58) 
Optimal 57.12 (55.04) 
0.230 0.700 (0.402-0.998) 22.00 73 75 
Non-optimal 31.34 (41.79) 
Act75 (%)
‡ 135.04 (112.20) 
Optimal 154.41 (115.07) 
0.162 0.733 (0.484-0.906) 30.02 87 50 
Non-optimal 58.65 (62.29) 
Act75-0(%)
§ 83.35 (81.48) 
Optimal 98.29 (85.34) 
  0.047* 0.817 (0.575-0.954) 57.98 67 100 
Non-optimal 27.32 (23.44) 
 enzyme activity measured prior to ERT infusion;  ‡ enzyme activity measured as the maximum concentration reached in leukocytes after ERT, measured 15 
min after infusion; § enzyme activity accumulated during the ERT, calculated as the difference between Act75 and Act0. SD: Standard deviation; ROC receiver 
operating curve; AUC: area under curve; Se: sensitivity: Sp: specificity.    * p<0.05 represents statistical significance of 5%. 
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TABLE 3. 
The correlation of the quantitative clinical variables and the Act75(%) and the Act75-0(%) and the 
averages of the individual clinical variables according to the cut-off point of 58% Act75-0. 
 
Variable Mean (SD) 
Correlation with   Mean according Act75-0 
Act75, r (p-value) Act75-0, r (p-value) ≥58% <58% p-value 
ActD 10.54 (9.07) 0.748 (0.0002)* 0.806 (0.00003)* 15.35 5.20 0.006* 
ZimranDiag 7.45 (3.64) -0.060 (0.861) -0.060 (0.861) 7.83 7.00 0.662 
Escala EVA 2.18 (2.46) -0.104 (0.692) -0.104 (0.692) 2.11 2.25 0.963 
%SF36FIS 48.12 (8.47) -0.248 (0.338) -0.248 (0.338) 45.68 50.88 0.167 
%SF36Ment 57.07 (8.70) -0.103 (0.694) -0.103 (0.694) 50.19 52.06 0.743 
SMRI 6.16 (6.87) -0.196 (0.421) -0.266 (0.271) 5.60 6.78 0.400 
GauSSI-I 4.63 (2.52) -0.461 (0.044)* -0.280 (0.246) 5.20 4.33 0.720 
 
ZimDiag: Zimran severity scale (SSI) to the diagnosis; %SF36FIS y %SF36Ment are physical and mental 
quality of life assessment using SF36; GauSSI-I: the Gaucher Severity Score Index-type I; S-MRI: scale 
for infiltration in the bone marrow; r: correlation coefficient. (* p<0.05 represents statistical 
significance of 5%). 
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FIGURE.1  
 
 
FIGURE CAPTIONS 
FIGURE.1 Receiver operating characteristic (ROC) curve for the Act75-0 (in percentage value) with 
optimal response (shown by the solid lines). Diagonal reference line is shown by the dotted lines. 
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0.817 (0.575-0.954) 
 
